You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK):降壓藥馬來酸依那普利片通過一致性評價
格隆匯 11-01 12:11

格隆匯11月1日丨石藥集團(01093.HK)宣佈,公司附屬公司石藥集團歐意藥業有限公司開發的“馬來酸依那普利片(10mg)”已獲中華人民共和國國家藥品監督管理局批准通過仿製藥質量和療效一致性評價。

依那普利為血管緊張素轉換酶抑制藥,主要用於治療各期原發性高血壓、腎血管性高血壓及各級心力衰竭。對於症狀性心衰病人可提高生存率、延緩心衰的進展、減少因心衰而導致的住院。並可預防症狀性心衰,以及左心室功能不全病人冠狀動脈缺血事件。

馬來酸依那普利片為集團治療高血壓的重點產品之一,是國內前三家通過一致性評價的同類產品。通過一致性評價,表示該產品與原研藥質量和療效一致,能為患者提供優質優價的用藥選擇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account